PT-141 (Bremelanotide) Protocol
FDA-approved melanocortin agonist for HSDD. Acts centrally via MC3R/MC4R pathways to enhance sexual desire.
Aug 27, 2026
1 min
FDA-approved melanocortin agonist for HSDD. Acts centrally via MC3R/MC4R pathways to enhance sexual desire.